Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study

This phase 3 multicenter study, including 26‐week treatment and extension periods, evaluated the efficacy and safety of adalimumab in Japanese patients with active ulcers due to pyoderma gangrenosum. Patients received adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every week starting a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Kenshi, Yamanaka, Keiichi, Zhao, Yiwei, Iwano, Shunsuke, Takei, Keiko, Suzuki, Koji, Yamamoto, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754463/
https://www.ncbi.nlm.nih.gov/pubmed/32804433
http://dx.doi.org/10.1111/1346-8138.15533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754463/
https://www.ncbi.nlm.nih.gov/pubmed/32804433
http://dx.doi.org/10.1111/1346-8138.15533

Ejemplares similares